Merck (MEX:MRK) Piotroski F-Score: 4 (As of Jun. 27, 2026) — 43% Below Median


MEX:MRK Merck & Co Inc MEX:MRK
72 GF Score
Price MXN2,241.00
GF Value MXN2,062.64
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Merck Piotroski F-Score?

Merck MEX:MRK +1.86% 72 Piotroski F-Score is 4 as of Jun. 27, 2026, which is 43% below its 10-year median of 7.00. GuruFocus rates MEX:MRK with a GF Score™ of 72/100 and a GF Value™ of MXN2,062.64 (Fairly Valued). The stock has 7 warning signs investors should review. Among 981 Drug Manufacturers companies, Merck ranks worse than 61.06% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Merck has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Merck's Piotroski F-Score or its related term are showing as below:

MEX:MRK' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 9
Current: 4

During the past 13 years, the highest Piotroski F-Score of Merck was 9. The lowest was 4. And the median was 7.

Merck  (MEX:MRK) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Merck Piotroski F-Score Related Terms


Merck Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Merck's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Piotroski F-Score Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 6.00 5.00 9.00 4.00

Merck Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.00 6.00 4.00 4.00

MEX:MRK vs ABBV, AMGN, GILD: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Merck's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Merck's Piotroski F-Score falls into.


MEX:MRK
72GF Score
Merck & Co Inc MEX:MRK
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 83356.868 + 106121.197 + 53350.889 + -76458.648 = MXN166,370 Mil.
Cash Flow from Operations was 62004.556 + 143488.332 + 51442.285 + 70652.119 = MXN327,587 Mil.
Revenue was 297614.335 + 316914.399 + 295293.48 + 293680.552 = MXN1,203,503 Mil.
Gross Profit was 230638.871 + 246197.508 + 195343.839 + 218033.376 = MXN890,214 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2355188.902 + 2212864.072 + 2376417.734 + 2464368.138 + 2320538.001) / 5 = MXN2345875.3694 Mil.
Total Assets at the begining of this year (Mar25) was MXN2,355,189 Mil.
Long-Term Debt & Capital Lease Obligation was MXN841,640 Mil.
Total Current Assets was MXN631,415 Mil.
Total Current Liabilities was MXN485,891 Mil.
Net Income was 99936.162 + 62162.277 + 78062.885 + 103907.198 = MXN344,069 Mil.

Revenue was 295173.5 + 327981.327 + 325849.457 + 317695.388 = MXN1,266,700 Mil.
Gross Profit was 226564.714 + 247644.903 + 246013.837 + 247748.802 = MXN967,972 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1756696.996 + 2063393.203 + 2314240.341 + 2442327.602 + 2355188.902) / 5 = MXN2186369.4088 Mil.
Total Assets at the begining of last year (Mar24) was MXN1,756,697 Mil.
Long-Term Debt & Capital Lease Obligation was MXN685,022 Mil.
Total Current Assets was MXN726,327 Mil.
Total Current Liabilities was MXN515,015 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Merck's current Net Income (TTM) was 166,370. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Merck's current Cash Flow from Operations (TTM) was 327,587. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=166370.306/2355188.902
=0.0706399

ROA (Last Year)=Net Income/Total Assets (Mar24)
=344068.522/1756696.996
=0.19586105

Merck's return on assets of this year was 0.0706399. Merck's return on assets of last year was 0.19586105. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Merck's current Net Income (TTM) was 166,370. Merck's current Cash Flow from Operations (TTM) was 327,587. ==> 327,587 > 166,370 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=841640.208/2345875.3694
=0.35877448

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=685022.369/2186369.4088
=0.31331502

Merck's gearing of this year was 0.35877448. Merck's gearing of last year was 0.31331502. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=631414.991/485891.102
=1.29949898

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=726327.475/515014.727
=1.41030428

Merck's current ratio of this year was 1.29949898. Merck's current ratio of last year was 1.41030428. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Merck's number of shares in issue this year was 2472. Merck's number of shares in issue last year was 2531. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=890213.594/1203502.766
=0.73968554

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=967972.256/1266699.672
=0.76416871

Merck's gross margin of this year was 0.73968554. Merck's gross margin of last year was 0.76416871. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1203502.766/2355188.902
=0.51100053

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1266699.672/1756696.996
=0.72106896

Merck's asset turnover of this year was 0.51100053. Merck's asset turnover of last year was 0.72106896. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Merck has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Merck (MEX:MRK) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Merck and its competitors. This is 43% below median its historical median of 7.00. Over the past decade, Merck's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, Merck ranks #599 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Merck's Piotroski F-Score too high?
Merck's current Piotroski F-Score of 4 is 43% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Merck's value of 4 is 20% below this industry median. Based on the distribution chart, Merck ranks #599 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Merck has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's Piotroski F-Score compare to ABBV and AMGN?
According to the Drug Manufacturers industry distribution chart, Merck ranks #599 out of 981 companies for Piotroski F-Score. This places Merck in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Merck's value of 4 is 20% below this benchmark. Historically, Merck's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Merck has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Merck and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck's current Piotroski F-Score is 4, which is 43% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (MEX:MRK) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,062.64, compared to a current price of MXN2,241.00 — trading 8.6% above its estimated fair value. The current Piotroski F-Score is 4, which is 43% below median its 10-year median of 7.00 and 20% below the Drug Manufacturers industry median of 5.00. Merck's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Merck (MEX:MRK), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (MEX:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of MXN2,241.00 is trading 8.6% above its estimated GF Value™ of MXN2,062.64. GuruFocus considers Merck to be Fairly Valued.

Key valuation signals for MEX:MRK:

  • Piotroski F-Score: 4 (43% below median its 10-year median of 7.00)
  • GF Value™: MXN2,062.64 vs. price of MXN2,241.00 (8.6% above fair value)
  • GF Score™: 72/100 with 7 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#599 of 981)

No single metric tells the full story. See the MEX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score

Get the complete analysis for MEX:MRK

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,241.00
Price
MXN2,062.64
GF Value